Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 17
2021 50
2022 95
2023 54
2024 111
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice.
Mattos M, Sacramento CQ, Ferreira AC, Fintelman-Rodrigues N, Pereira-Dutra FS, de Freitas CS, Gesto JSM, Temerozo JR, Silva APDD, Moreira MTG, Silva RSC, Silveira GPE, Pinto DP, Pereira HM, Fonseca LB, Alves Ferreira M, Blanco C, Viola JPB, Bou-Habib DC, Bozza PT, Souza TML. Mattos M, et al. Viruses. 2024 Nov 29;16(12):1856. doi: 10.3390/v16121856. Viruses. 2024. PMID: 39772165 Free PMC article.
It is thus necessary to study novel and repurposed antivirals for the treatment of COVID-19. We previously demonstrated that daclatasvir (DCV), an inhibitor of the hepatitis C virus (HCV) NS5A protein, impairs SARS-CoV-2 replication by targeting …
It is thus necessary to study novel and repurposed antivirals for the treatment of COVID-19. We previously demonstrated that d …
Molecular Insights into Structural Dynamics and Binding Interactions of Selected Inhibitors Targeting SARS-CoV-2 Main Protease.
Wang Y, Zhou Y, Khan FI. Wang Y, et al. Int J Mol Sci. 2024 Dec 16;25(24):13482. doi: 10.3390/ijms252413482. Int J Mol Sci. 2024. PMID: 39769245 Free PMC article.
The SARS-CoV-2 main protease (Mpro, also known as 3CLpro) is a key target for antiviral therapy due to its critical role in viral replication and maturation. ...These results underscore Nirmatrelvir's potential as a promising therapeutic agent for SARS …
The SARS-CoV-2 main protease (Mpro, also known as 3CLpro) is a key target for antiviral therapy due to its critical rol …
An isothermal calorimetry assay for determining steady state kinetic and Ensitrelvir inhibition parameters for SARS-CoV-2 3CL-protease.
Mazzei L, Ranieri S, Silvestri D, Greene-Cramer R, Cioffi C, Montelione GT, Ciurli S. Mazzei L, et al. Sci Rep. 2024 Dec 31;14(1):32175. doi: 10.1038/s41598-024-81990-y. Sci Rep. 2024. PMID: 39741150 Free PMC article.
This manuscript details the application of Isothermal Titration Calorimetry (ITC) to characterize the kinetics of 3CL(pro), the main protease from the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), and its inhibition by Ensitrelvir, a known non …
This manuscript details the application of Isothermal Titration Calorimetry (ITC) to characterize the kinetics of 3CL(pro), the main proteas …
Impact of oral early antiviral therapies for mild-moderate COVID-19 in the outpatient's setting during Omicron era: a pharmacoeconomic analysis.
Scaglione V, Gardin S, Sasset L, Presa N, Rossetto A, Boemo DG, Silvola S, Restelli U, Cattelan A. Scaglione V, et al. Eur J Med Res. 2024 Dec 19;29(1):597. doi: 10.1186/s40001-024-02154-2. Eur J Med Res. 2024. PMID: 39696409 Free PMC article.
BACKGROUND: Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality and hospital admissions in high-risk patients with mild to moderate COVID-19. Nevertheless, there is a lack of data about the pharmacoeconomic impact of these antivirals in the Omicr …
BACKGROUND: Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) decreased mortality and hospital admissions in high-risk patients with mild …
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.
Gentile I, Viceconte G, Cuccurullo F, Pietroluongo D, D'Agostino A, Silvitelli M, Mercinelli S, Scotto R, Grimaldi F, Palmieri S, Gravetti A, Trastulli F, Moccia M, Buonomo AR. Gentile I, et al. Ann Med. 2025 Dec;57(1):2439541. doi: 10.1080/07853890.2024.2439541. Epub 2024 Dec 11. Ann Med. 2025. PMID: 39661366 Free PMC article.
However, only the latter factor was independently associated with a longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants. CONCLUSIONS: Early administration of combination th …
However, only the latter factor was independently associated with a longer SARS-CoV-2 infection, suggesting a loss of e …
Maple syrup urine disease diagnosed in a resource-limited setting in an infant in Nepal: a case report.
Baidya S, Thapa J, Kadel A, Kharal N, Lamichhane M, Dubey RK, Raut M, Bhattarai A, Tuladhar ET, Sharma VK, Niraula A. Baidya S, et al. BMC Pediatr. 2024 Nov 27;24(1):770. doi: 10.1186/s12887-024-05266-0. BMC Pediatr. 2024. PMID: 39604949 Free PMC article.
This case highlights MSUD diagnosed in association with COVID-19 complications from Nepal. CASE PRESENTATION: We present a case of a 4-month-old child with a biochemical diagnosis of flared-up MSUD. ...An incessant peculiar odor emanating from the child led to stron …
This case highlights MSUD diagnosed in association with COVID-19 complications from Nepal. CASE PRESENTATION: We present a cas …
Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022.
Wang FD, Nguyen PA, Lee D, Taysi B, Lefebvre d'Hellencourt F, Spinardi J, Phuc PT, Burton W, Chang YH, Hien NTK, Lin SM, Chieh Y, Kyaw MH, Hsu JC. Wang FD, et al. J Glob Health. 2024 Nov 8;14:05032. doi: 10.7189/jogh.14.05032. J Glob Health. 2024. PMID: 39513295 Free PMC article.
BACKGROUND: Antivirals are effective in reducing hospitalisation and death in mild-to-moderate coronavirus 2019 (COVID-19) patients. We estimated the antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with a syndrome coronavirus 2 (SARS …
BACKGROUND: Antivirals are effective in reducing hospitalisation and death in mild-to-moderate coronavirus 2019 (COVID-19) pat …
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients.
Saheb Sharif-Askari F, Ali Hussain Alsayed H, Saheb Sharif-Askari N, Al Sayed Hussain A, Al-Muhsen S, Halwani R. Saheb Sharif-Askari F, et al. Sci Rep. 2024 Oct 29;14(1):25901. doi: 10.1038/s41598-024-76472-0. Sci Rep. 2024. PMID: 39472619 Free PMC article.
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain. This retrospective cohort study assessed the …
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. …
Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M(pro) from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants.
Wang X, Gotchev D, Fan KY, Vega MM, Mani N, McGovern-Gooch K, Cuconati A, Tercero B, Wang X, Carpino P, Maskos K, Centrella PA, Schmitt A, Preuss F, Prasad A, Chen CY, Clark MA, Guilinger JP, Johnstone S, von König K, Keefe AD, Liu J, Turcotte S, Zhang Y, Konz Makino DL, Lam AM, Cole AG, Sofia MJ. Wang X, et al. J Med Chem. 2024 Nov 14;67(21):19623-19667. doi: 10.1021/acs.jmedchem.4c02009. Epub 2024 Oct 25. J Med Chem. 2024. PMID: 39453309
The recent global COVID-19 pandemic has highlighted treatments for coronavirus infection as an unmet medical need. The main protease (M(pro)) has been an important target for the development of SARS-CoV-2 direct-acting antivirals. Nirmatrelvir a …
The recent global COVID-19 pandemic has highlighted treatments for coronavirus infection as an unmet medical need. The main pr …
Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
Lo CW, Kariv O, Hao C, Gammeltoft KA, Bukh J, Gottwein J, Westberg M, Lin MZ, Einav S. Lo CW, et al. Antiviral Res. 2024 Nov;231:106022. doi: 10.1016/j.antiviral.2024.106022. Epub 2024 Oct 17. Antiviral Res. 2024. PMID: 39424074 Free article.
There is an ongoing need to expand the anti-SARS-CoV-2 armamentarium to include agents capable of suppressing replication of drug-resistant mutants emerging during monotherapy with approved direct-acting antivirals. ...Thus, ML2006a4 represents an attractive …
There is an ongoing need to expand the anti-SARS-CoV-2 armamentarium to include agents capable of suppressing replicati …
293 results